表紙
市場調査レポート

Active Biotech ABの製品パイプライン分析

Active Biotech AB - Product Pipeline Review - 2014

発行 Global Markets Direct 商品コード 192433
出版日 ページ情報 英文 33 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.95円で換算しております。
Back to Top
Active Biotech ABの製品パイプライン分析 Active Biotech AB - Product Pipeline Review - 2014
出版日: 2014年05月30日 ページ情報: 英文 33 Pages
概要

バイオテクノロジー企業であるActive Biotech ABでは、主に自己免疫/炎症性疾患、癌治療薬の研究、商品化に取り組んでいます。

当レポートでは、Active Biotech ABにおける治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

Active Biotech ABの基本情報

Active Biotech ABの概要

  • 主要情報
  • 企業情報

Active Biotech AB:R&Dの概要

  • 主な治療範囲

Active Biotech AB:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品
  • アウトライセンス製品
    • アウトライセンス製品/併用療法モダリティ

Active Biotech AB:パイプライン製品の概況

  • 最終段階にあるパイプライン製品
    • 第III相にある製品/併用療法モダリティ
  • 治験段階にあるパイプライン製品
    • 第II相にある製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • 前臨床段階にある製品/併用療法モダリティ

Active Biotech AB:薬剤プロファイル

  • tasquinimod
  • naptumomab estafenatox
  • paquinimod
  • ISI

Active Biotech AB:パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

Active Biotech AB:最近のパイプライン動向

Active Biotech AB:休止中のプロジェクト

Active Biotech AB:開発が中止されたパイプライン製品

  • 開発が中止されたパイプライン製品のプロファイル
  • ABR-224050

Active Biotech AB:本社と子会社の所在地

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC04892CDB

Global Markets Direct's, 'Active Biotech AB - Product Pipeline Review - 2014', provides an overview of the Active Biotech AB's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Active Biotech AB's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Active Biotech AB including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Active Biotech AB's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Active Biotech AB's pipeline products

Reasons to buy

  • Evaluate Active Biotech AB's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Active Biotech AB in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Active Biotech AB's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Active Biotech AB and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Active Biotech AB
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Active Biotech AB and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Active Biotech AB Snapshot
    • Active Biotech AB Overview
    • Key Information
    • Key Facts
  • Active Biotech AB - Research and Development Overview
    • Key Therapeutic Areas
  • Active Biotech AB - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Active Biotech AB - Pipeline Products Glance
    • Active Biotech AB - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Active Biotech AB - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
    • Active Biotech AB - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Active Biotech AB - Drug Profiles
    • tasquinimod
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • naptumomab estafenatox
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • paquinimod
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ISI
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Active Biotech AB - Pipeline Analysis
    • Active Biotech AB - Pipeline Products by Target
    • Active Biotech AB - Pipeline Products by Route of Administration
    • Active Biotech AB - Pipeline Products by Molecule Type
    • Active Biotech AB - Pipeline Products by Mechanism of Action
  • Active Biotech AB - Recent Pipeline Updates
  • Active Biotech AB - Dormant Projects
  • Active Biotech AB - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • ABR-224050
  • Active Biotech AB - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Active Biotech AB, Key Information
  • Active Biotech AB, Key Facts
  • Active Biotech AB - Pipeline by Indication, 2014
  • Active Biotech AB - Pipeline by Stage of Development, 2014
  • Active Biotech AB - Monotherapy Products in Pipeline, 2014
  • Active Biotech AB - Out-Licensed Products in Pipeline, 2014
  • Active Biotech AB - Out-Licensed Products/ Combination Treatment Modalities, 2014
  • Active Biotech AB - Phase III, 2014
  • Active Biotech AB - Phase II, 2014
  • Active Biotech AB - Preclinical, 2014
  • Active Biotech AB - Pipeline by Target, 2014
  • Active Biotech AB - Pipeline by Route of Administration, 2014
  • Active Biotech AB - Pipeline by Molecule Type, 2014
  • Active Biotech AB - Pipeline Products by Mechanism of Action, 2014
  • Active Biotech AB - Recent Pipeline Updates, 2014
  • Active Biotech AB - Dormant Developmental Projects,2014
  • Active Biotech AB - Discontinued Pipeline Products, 2014
  • Active Biotech AB, Subsidiaries

List of Figures

  • Active Biotech AB - Pipeline by Top 10 Indication, 2014
  • Active Biotech AB - Pipeline by Stage of Development, 2014
  • Active Biotech AB - Monotherapy Products in Pipeline, 2014
  • Active Biotech AB - Out-Licensed Products in Pipeline, 2014
  • Active Biotech AB - Pipeline by Top 10 Target, 2014
  • Active Biotech AB - Pipeline by Top 10 Route of Administration, 2014
  • Active Biotech AB - Pipeline by Top 10 Molecule Type, 2014
  • Active Biotech AB - Pipeline Products by Top 10 Mechanism of Action, 2014
Back to Top